Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: harkenman who wrote (287)	4/30/1999 9:35:00 PM
From: Miljenko Zuanic	Read Replies (2) \| Respond to of 3559

<<Warner-Lambert's Chief Says Company Is Open to Acquisitions Any impact to REGN?>> NO! REGN is reserved for P&G! :) Today 1Q report: biz.yahoo.com <<At March 31, 1999, Regeneron had $104.6 million in cash and marketable securities, compared to $113.5 million at December 31, 1998. Beginning in the third quarter of 1999, Procter & Gamble's support of research and development activities at Regeneron, in addition to amounts paid to support development of AXOKINE which vary from quarter to quarter, will increase from $1.1 million per quarter to at least $6.3 million per quarter for the following three years of the companies' long-term collaboration agreement. >> This is commitment of big 75 M!!! So, dear fellow investors and lurks of all kind, WHAT IS WRONG? Who the hell is selling stock at ~6???? Talk to me!!! Miljenko